Prometic Biosciences Inc.

E. R. Squibb Sons, Inc.

Novo Nordisk A/s

James Christopher Pearson

Steven James Burton

Peter A Edwardson

Jason Richard Betley

Ben Martin Beacom

Helen Rosemary Tatton

Tadeusz Antoni Podgorski

Robert William Pannell

Christopher R Lowe

Patrick Vasconcelos Gurgel

Peter A D Edwardson

Baldev Singh Baines

Abid Hussain

Claudia Hildegard Kuhn

Alan Menzies

David Johnson Stewart

Rongxiu Li

Kenneth Sproule

For the separation, removal, isolation, purification, characterisation, identification or quantification of fibrinogen or a protein that is a fibrinogen analogue, an affinity adsorbent is used that is a compound of formula II wherein one X is N and the other is N, C&#x2014;CI or C&#x2014;CN;

Affinity adsorbents for fibrinogen

For the separation, removal, isolation, purification, characterization, identification or quantification of fibrinogen or a protein that is a fibrinogen analogue, an affinity adsorbent is used that is a compound of formula II wherein one X is N and the other is N, C&#x2014;Cl or C&#x2014;CN; Y is O, S or NR; 0 Z is O, S or NR; Rand Rare each H, alkyl, hydroxyalkyl, benzyl or &bgr; -phenylethyl; n is 0 to 6; A is a support matrix, optionally linked to the triazine ring by a spacer; Ris a group bearing a positive charge at neutral pH; W is an optional linker; V is an aromatic group; and Rand Rare each H, OH, alkyl, alkoxy, amino, NH, acyloxy, acylamino, COH, sulphonic acid, carbamoyl, sulphamoyl, alkylsulphonyl or halogen or a cyclic structure such as a morpholino group, or Rand Rare linked to form such a cyclic structure.

Compounds of the general formula (I): in which inter alia Qrepresents &#x2014;NRR, &#x2014;ORor &#x2014;SRand Qrepresents &#x2014;NRR, &#x2014;ORor &#x2014;SR, and A represents the point of attachment to a support matrix, are useful as protein binding ligands when (a) at least one of R, R, Rand Rincludes an alkyl group &#x2014;CHin which n is greater than or equal to 7; (b) at least two of R, R, Rand Rindependently include an alkyl group &#x2014;CHor a cycloalkyl group &#x2014;CHin which n is greater than or equal to 4; or (c) at least three of R, R, Rand Rindependently include a Calkyl group substituted by &#x2014;NRRor aryl. 

Triazines and pyrimidines as protein binding ligands

Compounds of formula (I) wherein Rand Rare the same or different and are each optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl groups; Ris hydrogen or an aryl group substituent or Ris a solid support optionally attached via a spacer; Z represents an oxygen atom, a sulphur atom or NR; Y represents an oxygen atom, a sulphur atom or NR; in which Rand R, which may be the same or different, represent hydrogen, optionally substituted alkyl containing 1 to 6 carbon atoms, optionally substituted phenyl, optionally substituted benzyl or optionally substituted &#x3b2;-phenylethyl; and one of Xand Xrepresents a nitrogen atom and the other of Xand Xrepresents a nitrogen atom or CR, in which Rrepresents hydrogen or an aryl group substituent; are useful for the affinity binding of a prion protein. 

Substituted triazines as prion protein ligands and their use to detect or remove prions

For the separation, removal, isolation, purification, characterization, identification or quantification of plasminogen or a protein that is a plasminogen analogue, an affinity adsorbent is used that is a compound of formula (II) wherein one X is N and the other is N, C&#x2014;Cl or C&#x2014;CN; A is a support matrix, optionally linked to the triazine ring by a spacer; Z is O, S or N&#x2014;R and R is H, Calkyl, Chydroxyalkyl, benzyl or &bgr;-phenylethyl; B is an optionally substituted hydrocarbon linkage containing from 1 to 10 carbon atoms; D is H, OH or a primary amino, secondary amino, tertiary amino, quaternary ammonium, imidazole, guanidino or amidino group; or B-D is &#x2014;CHCOOH&#x2014;(CH)&#x2014;NH; and q is 2 to 6.

Affinity adsorbents for plasminogen

A compound of the formula (I) wherein each Z is the same or different and is formula (a) or &#x2014;Y wherein each X is the same or different and is a multivalent aminyl group or diaminyl-terminated spacer; each Y is the same or different aminyl group; and M is a support matrix. 

Triazine compounds and their use in forming multidimensional libraries for affinity chromatography

Stable compositions containing biotinylated molecules, such as enzymes, are provided. The compositions include a biotinylated biomolecule, a biomolecule protectant, a buffer, a bulking agent selected from one or more water soluble, nonionic polymers and preferably a terminal sterilization protectant. The compositions can be utilized either as aqueous solutions or preferably in dried form, e.g., as a lyophilized, powder cake. They have applicability in any case where avidin/biotin technology is used and are particularly important as compositions containing a thrombin-like enzyme, e.g., for preparation of a fibrin monomer and fibrin monomer-based fibrin sealants.

Stable biotinylated biomolecule composition

The present invention relates to novel affinity ligand-matrix conjugates comprising a ligand with the general formula (a) ##STR1## which ligand is attached to a support matrix in position (A), optionally through a spacer arm interposed between the matrix and ligand. The invention furthermore relates to these novel affinity ligand-matrix conjugates and the preparation and use thereof in the purification of proteinaceous materials such as e.g. immunoglobulins, insulins, Factor VII, or human Growth Hormone or analogues, derivatives and fragments thereof and precursors.

Triazine based ligands and use thereof

Compositions and methods for avidin immobilized on an inert support material, e.g. agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants. The fibrin is prepared by subjecting a fibrinogen-containing composition to a biotinylated enzyme to convert the fibrinogen in the composition to a corresponding fibrin monomer. A fibrin monomer/biotinylated enzyme mixture is formed. A material comprising an avidin/inert support composition having 1000 biotin binding units of activity per gram of the composition, a bulking agent and a protectant, is then introduced into the enzyme mixture to form a complex of the material and the biotinylated enzyme. The complex and enzyme are then removed therefrom to recover a fibrin monomer. Bulking agents selected from nonionic water soluble compounds are used.

Method of producing a fibrin monomer using a biotinylated enzyme and

Compositions and methods for avidin or protein having affinity for biotin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels for binding biotin and may include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the composition during lyophilization and terminal sterilization processes. The compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomers useful for fibrin sealants.

Stable composition of immobilized protein having affinity for biotin

Compositions and methods for avidin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. A dry composition, and wet compositions such as a gel, slurry or suspension having avidin immobilized on an inert support material are disclosed. The dry composition has at least 1000 biotin binding units of activity, and the wet compositions have at least 50 units of binding activity. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants.

Gel, slurry or suspension containing immobilized avidin having high

Compositions and methods for avidin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants.

Growing community of inventors

Cambridge, United Kingdom

James Christopher Pearson